Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings Incyte Corporation: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Highlights: Incyte Corporation
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.
Weaknesses: Incyte Corporation
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • With an expected P/E ratio at 16.88 and 15.51 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

Incyte Corporation SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Incyte Corporation SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Incyte Corporation SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Incyte Corporation SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Incyte Corporation SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
20.55B
AA
76.88B
A
59.21B
BBB
57.42B
AA
56.2B
AA
25.32B
AA
18.4B
AAA
13.64B
CCC
19.46B -
A
- -
15.06B -
BB
- -
Average 36.21B
A
Weighted average by Cap.
A
See all sector ratings
  1. Stock Market
  2. Equities
  3. INCY Stock
  4. Ratings Incyte Corporation